# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2024

## INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

0-26224 51-0317849 (IRS Employer Identification (State or Other Jurisdiction of Incorporation (Commission File Number) or Organization) No.)

#### 1100 Campus Road Princeton, NJ 08540

(Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (609) 275-0500

(Former name or	r former address, if changed sine	ce last report)
Check the appropriate box below if the Form 8-K filing is intended following provisions (see General Instruction A.2. below):	ded to simultaneously satisfy the	e filing obligation of the registrant under any of the
☐ Written communications pursuant to Rule 425 under the Secu	urities Act (17 CFR 230.425).	
☐ Soliciting material pursuant to Rule 14a-12 under the Exchan	nge Act (17 CFR 240.14a-12).	
☐ Pre-commencement communications pursuant to Rule 14d-2	(b) under the Exchange Act (17	CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(	(c) under the Exchange Act (17	CFR 240.13e-4(c)).
Securities Registered Pursuant to Section12(b) of the Act:		
<u>Title of Each Class</u> Common Stock, Par Value \$.01 Per Share	Trading Symbol IART	Name of Exchange on Which Registered Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (		n Rule 405 of the Securities Act of 1933 (§230.405 of this
Emerging growth company □		
If an emerging growth company, indicate by check mark if the por revised financial accounting standards provided pursuant to S	_	_

### ITEM 8.01 OTHER EVENTS

On May 16, 2024, Integra LifeSciences Holdings Corporation (the "Company") entered into an accelerated share repurchase agreement with Morgan
Stanley & Co. LLC to repurchase \$50 million in the aggregate of the Company's outstanding shares of common stock, par value \$0.01 per share. The
repurchase transactions are expected to be completed in the third quarter of 2024.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: May 16, 2024 By: /s/ Lea Knight

Lea Knight

Title: Executive Vice President and Chief Financial Officer